Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When you research Progyny, the first numbers you chase are live-birth success rates, employer contract renewals, and network clinic costs. Those details hide inside dense SEC documents, not glossy press releases. This page gathers every Progyny SEC filing explained simply, so you no longer sift through hundreds of pages to verify margin trends or Smart Cycle utilization rates.
Use our AI-powered summaries to jump directly to what matters: the Progyny annual report 10-K simplified spotlights outcome statistics and revenue per member, while the latest Progyny quarterly earnings report 10-Q filing breaks down reimbursement shifts and new client wins. Sudden contract announcements? The Progyny 8-K material events explained section flags them within minutes of hitting EDGAR. If you’re tracking leadership incentives, our system streams Progyny Form 4 insider transactions real-time, alerting you to every Progyny executive stock transactions Form 4.
Here’s how professionals use the page:
- Compare quarter-over-quarter embryo transfer success rates with one-click Progyny earnings report filing analysis.
- Monitor governance changes through the Progyny proxy statement executive compensation link to gauge retention costs.
- Stay ahead of market moves with instant notifications on Progyny insider trading Form 4 transactions.
The 07/05/2025 Form 4 shows CECO Environmental Corp.’s Chief Accounting Officer, Kiril Kovachev, surrendering 460 common shares at an indicated price of $30 per share under Transaction Code “F.” Code F denotes shares withheld by the issuer solely to cover statutory taxes triggered by the vesting of previously awarded restricted stock units; it is not an open-market sale. After the withholding, Kovachev’s direct ownership stands at 15,114 shares, and no derivative positions were reported. Because the filing reflects an administrative, tax-related adjustment rather than a discretionary buy or sell decision, the event carries limited signalling value for investors.
SEC Form 4 filed for First Guaranty Bancshares, Inc. (FGBI) discloses that director Edgar R. Smith III markedly increased his ownership on 30 June 2025.
- Open-market purchase: 30,865 common shares acquired at $8.10 (Code P).
- Debt-for-equity exchange: 1,981,506 new shares issued at $7.57 in exchange for a $15 million floating-rate subordinated note under an Exchange Agreement dated 16 June 2025.
- Note amendments: 88,482 shares issued at $8.00 to Smith & Tate Investments, LLC pursuant to amendments to an existing promissory note and a subordinated note.
Following these transactions, Smith reports 2,852,467 shares held directly. Indirectly, he controls additional positions through several LLCs, including Smith & Hood Holding Company, LLC (1,062,817 shares) and three other investment entities, taking total reported beneficial ownership well above three million shares.
The filing signals a net addition of roughly 2.1 million shares, replacing interest-bearing debt with equity and reflecting continued insider confidence. Because the new shares were issued below recent market purchases ($7.57 vs. $8.10), the company reduces debt at a valuation apparently acceptable to both parties while the director deepens alignment with common shareholders.
Form 4 filing for UnitedHealth Group (UNH) dated 07/02/2025 discloses routine quarterly equity compensation to non-employee director Paul R. Garcia.
- Transactions (07/01/2025): 173 deferred stock units (immediately vested, must be held until board service ends) and 96 shares of common stock, both awarded at $0 cost.
- Post-transaction ownership: 2,750 common shares held directly; 2,146 shares in a revocable trust; 45 and 55 shares in two additional trusts, for a total indirect holding of 2,246 shares.
- No derivative securities were acquired or disposed of; the filing cites the awards as regular quarterly director compensation, not incentive-based or market purchases.
The filing is administrative in nature, with no impact on company operations, capital structure, or insider sentiment beyond customary board compensation.
FAQ
What is the current stock price of Progyny (PGNY)?
What is the market cap of Progyny (PGNY)?
What is Progyny, Inc. and what services do they provide?
How does Progyny’s business model work?
What distinguishes Progyny from other fertility benefit providers?
Who are Progyny’s primary clients?
How does Progyny leverage technology in its services?
What are Smart Cycles and how do they benefit patients?
How does Progyny manage its provider network?
What kind of support does Progyny offer to its members?
